JPMorgan Chase & Co. raised its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 308.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 500,499 shares of the biotechnology company’s stock after purchasing an additional 378,002 shares during the quarter. JPMorgan Chase & Co. owned 1.15% of United Therapeutics Corporation worth $64,930,000 at the end of the most recent reporting period.
Several other hedge funds also recently made changes to their positions in UTHR. Focused Wealth Management Inc lifted its holdings in shares of United Therapeutics Corporation by 17.5% in the 1st quarter. Focused Wealth Management Inc now owns 940 shares of the biotechnology company’s stock valued at $127,000 after buying an additional 140 shares during the period. Daiwa Securities Group Inc. lifted its holdings in shares of United Therapeutics Corporation by 17.4% in the 1st quarter. Daiwa Securities Group Inc. now owns 1,350 shares of the biotechnology company’s stock valued at $183,000 after buying an additional 200 shares during the period. Campbell & CO Investment Adviser LLC acquired a new stake in shares of United Therapeutics Corporation in the 1st quarter valued at approximately $204,000. Eagle Global Advisors LLC acquired a new stake in shares of United Therapeutics Corporation in the 2nd quarter valued at approximately $206,000. Finally, Clarity Capital KCPS Ltd. acquired a new stake in shares of United Therapeutics Corporation in the 1st quarter valued at approximately $230,000.
Several research firms have recently commented on UTHR. UBS AG reissued a “sell” rating and issued a $106.00 price target on shares of United Therapeutics Corporation in a report on Thursday, July 6th. ValuEngine raised United Therapeutics Corporation from a “buy” rating to a “strong-buy” rating in a report on Thursday, July 13th. BidaskClub cut United Therapeutics Corporation from a “buy” rating to a “hold” rating in a report on Wednesday, July 19th. Jefferies Group LLC reissued a “sell” rating and issued a $105.00 price target on shares of United Therapeutics Corporation in a report on Friday, July 14th. Finally, Zacks Investment Research cut United Therapeutics Corporation from a “hold” rating to a “sell” rating in a report on Thursday, July 13th. Six equities research analysts have rated the stock with a sell rating, seven have given a hold rating and two have given a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $134.50.
In other news, CEO Martine A. Rothblatt sold 1,232 shares of the stock in a transaction on Thursday, September 7th. The stock was sold at an average price of $133.32, for a total value of $164,250.24. Following the completion of the sale, the chief executive officer now owns 2,301 shares in the company, valued at $306,769.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Christopher Causey sold 580 shares of the stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $134.48, for a total value of $77,998.40. Following the completion of the sale, the director now owns 3,295 shares of the company’s stock, valued at approximately $443,111.60. The disclosure for this sale can be found here. Insiders have sold a total of 25,178 shares of company stock valued at $3,289,427 in the last quarter. Insiders own 7.80% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece on another site, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The correct version of this piece can be accessed at https://sportsperspectives.com/2017/09/12/jpmorgan-chase-co-has-64-93-million-holdings-in-united-therapeutics-corporation-uthr.html.
United Therapeutics Corporation (NASDAQ UTHR) opened at 120.75 on Tuesday. United Therapeutics Corporation has a one year low of $110.90 and a one year high of $169.89. The company’s 50-day moving average price is $130.11 and its 200 day moving average price is $130.35. The firm has a market capitalization of $5.25 billion, a PE ratio of 14.00 and a beta of 1.52.
United Therapeutics Corporation (NASDAQ:UTHR) last announced its quarterly earnings data on Thursday, July 27th. The biotechnology company reported ($1.25) EPS for the quarter, missing analysts’ consensus estimates of $3.61 by $4.86. United Therapeutics Corporation had a net margin of 24.18% and a return on equity of 20.96%. The company had revenue of $444.60 million for the quarter, compared to analyst estimates of $391.53 million. During the same quarter last year, the company posted $4.42 EPS. United Therapeutics Corporation’s revenue was up 7.8% on a year-over-year basis. On average, analysts forecast that United Therapeutics Corporation will post $10.09 earnings per share for the current year.
United Therapeutics Corporation Profile
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR).
Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.